Outbreaks | 2014 | 2015 | 2016 | 2017 | 2018 | Total |
---|---|---|---|---|---|---|
n (%) | n (%) | |||||
Identified | 13 | 16 | 2 | 19 | 12 | 62 |
Investigated with serological testing | 9 (69) | 7 (44) | 2 (100) | 17 (89) | 10 (83) | 45 (73) |
Confirmed by serologic testing | 9 (69) | 7 (44) | 0 (—) | 16 (84) | 4 (33) | 36 (58) |
Cases, median (range) | 14 (8–45) | 35 (23–73) | 0 (—) | 17 (9–31) | 15 (6–22) | 17 (6–73) |
Days (range) | ||||||
Duration, median | 29 (9–91) | 60 (28–93) | 60 (29–91) | 42 (9–84) | 34 (8–71) | 42 (8–93) |
Median lag from rash onset in first case to notification | 23 (1–90) | 46 (18–82) | 53 (23–84) | 53 (0–91) | 22 (0–74) | 23 (0–90) |
Median lag from notification to investigation | 13 (3–28) | 14 (10–22) | 8 (7–10) | 8 (3–21) | 12 (3–26) | 13 (3–28) |
Confirmed cases | n (%) | n (%) | ||||
Number | 158 | 295 | — | 279 | 155 | 887 |
Age (yrs), median (range) | 4 (0–35) | 3 (0–25) | — | 5 (0–30) | 4 (0–13) | 4 (0–35) |
<1 year | 27 (17) | 30 (10) | — | 31 (11) | 15 (10) | 103 (12) |
1–4 years | 76 (48) | 142 (48) | — | 137 (49) | 52 (34) | 407 (46) |
5–9 years | 40 (25) | 107 (36) | — | 92 (33) | 77 (50) | 316 (36) |
10-14 years | 12 (8) | 12 (4) | — | 16 (6) | 11 (7) | 51 (6) |
≥15 years | 3 (2) | 4 (1) | — | 3 (1) | 0 (—) | 10 (1) |
Sex, male | 70 (44) | 142 (48) | — | 158 (57) | 87 (56) | 457 (52) |
Religious minority | 79 (50) | 166 (56) | — | 116 (42) | 21 (14) | 382 (43) |
Vaccination status | ||||||
MCV 1 | 26 (16) | 21 (7) | — | 49 (18) | 14 (9) | 110 (12) |
MCV 2 | 11 (7) | 5 (2) | — | 44 (16) | 20 (13) | 80 (9) |
Unvaccinated | 103 (65) | 246 (83) | — | 146 (52) | 96 (62) | 591 (67) |
Unknown | 18 (11) | 23 (8) | — | 40 (14) | 25 (16) | 106 (12) |